CPT 81450: Targeted Genomic Panel for Hematolymphoid Neoplasms
Commercial payers pay $765 on average nationally for this procedure.
CPT code 81450 describes a targeted genomic sequence analysis panel for hematolymphoid neoplasms, performing DNA and possibly RNA sequencing of 5–50 genes to evaluate blood or bone marrow specimens for clinically significant genomic alterations; service type: targeted genomic sequencing panel for hematolymphoid neoplasms; typical site of service: clinical molecular pathology laboratory or hospital-based lab processing blood or bone marrow samples.
For related coverage guidance, see recent payer policy updates: RTM Testing of Homocysteine Metabolism-Related Conditions, Multimarker Serum Testing Related to Ovarian Cancer, Genomic Profiling for Selecting Targeted Cancer Therapies.
Customize your policy alerts
Sign up for cpt 81450 policy alerts
Get alerted when payer policies referencing 81450 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial pricing for CPT 81450 centers around BUCA’s average commercial rate of $765.10, which serves as a useful mid-market reference. Blue Cross Blue Shield shows the highest dispersion between its 25th and 75th percentiles (range = $301.90), reflecting more variability in negotiated rates; Cigna and BUCA also display wide interquartile spreads ($704.40 and $368.50 respectively), while Aetna and UnitedHealth Group exhibit tighter distributions (Aetna range = $176.00; UnitedHealth Group range = $177.10). These ranges indicate meaningful differences in rate concentration across carriers rather than uniform pricing.
Examining central tendency, Cigna and Blue Cross Blue Shield have higher mean rates ($865.00 and $858.80) compared with Aetna and UnitedHealth Group (means of $527.30 and $528.50), with BUCA’s mean sitting at $765.10 between those groups. The largest absolute outliers in maximum values are with Blue Cross Blue Shield ($4,676.00) and Cigna ($2,899.70), suggesting occasional very high allowed amounts, whereas Aetna and UnitedHealth Group have much lower documented maxima.